Ameriprise’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-61,449
| Closed | -$63.9K | – | 4094 |
|
|
2024
Q3 | $63.9K | Hold |
61,449
| – | – | ﹤0.01% | 3870 |
|
|
2024
Q2 | $106K | Buy |
+61,449
| New | +$124K | ﹤0.01% | 3770 |
|
|
2024
Q1 | – | Sell |
-13,666
| Closed | -$45.5K | – | 3860 |
|
|
2023
Q4 | $45.5K | Sell |
13,666
-476,077
| -97% | -$1.28M | ﹤0.01% | 3854 |
|
|
2023
Q3 | $1.83M | Sell |
489,743
-256,422
| -34% | -$1.18M | ﹤0.01% | 2859 |
|
|
2023
Q2 | $3.19M | Sell |
746,165
-621,655
| -45% | -$3.67M | ﹤0.01% | 2636 |
|
|
2023
Q1 | $9.36M | Sell |
1,367,820
-458,876
| -25% | -$3.56M | ﹤0.01% | 1827 |
|
|
2022
Q4 | $14.5M | Buy |
1,826,696
+585
| +0% | +$4.5K | 0.01% | 1437 |
|
|
2022
Q3 | $17.5M | Sell |
1,826,111
-117,892
| -6% | -$1.19M | 0.01% | 1267 |
|
|
2022
Q2 | $14.1M | Buy |
1,944,003
+86,871
| +5% | +$755K | ﹤0.01% | 1472 |
|
|
2022
Q1 | $24M | Buy |
1,857,132
+169,307
| +10% | +$2.15M | 0.01% | 1213 |
|
|
2021
Q4 | $26.9M | Buy |
1,687,825
+296,981
| +21% | +$5.19M | 0.01% | 1199 |
|
|
2021
Q3 | $22.4M | Buy |
1,390,844
+130
| +0% | +$1.91K | 0.01% | 1184 |
|
|
2021
Q2 | $19.2M | Buy |
1,390,714
+140,705
| +11% | +$1.99M | 0.01% | 1390 |
|
|
2021
Q1 | $18.3M | Sell |
1,250,009
-661,998
| -35% | -$11.2M | 0.01% | 1391 |
|
|
2020
Q4 | $33.2M | Sell |
1,912,007
-453,721
| -19% | -$8.08M | 0.01% | 936 |
|
|
2020
Q3 | $43.4M | Sell |
2,365,728
-1,464,385
| -38% | -$27.2M | 0.02% | 695 |
|
|
2020
Q2 | $68.4M | Buy |
3,830,113
+391,779
| +11% | +$6.63M | 0.03% | 504 |
|
|
2020
Q1 | $55.8M | Buy |
3,438,334
+1,880,196
| +121% | +$34.7M | 0.03% | 508 |
|
|
2019
Q4 | $28.1M | Buy |
1,558,138
+871,346
| +127% | +$16.1M | 0.01% | 969 |
|
|
2019
Q3 | $13.9M | Buy |
686,792
+498,282
| +264% | +$9.96M | 0.01% | 1427 |
|
|
2019
Q2 | $4.17M | Sell |
188,510
-360,813
| -66% | -$6.27M | ﹤0.01% | 2347 |
|
|
2019
Q1 | $7.49M | Buy |
549,323
+31,205
| +6% | +$416K | ﹤0.01% | 1934 |
|
|
2018
Q4 | $4.69M | Buy |
518,118
+333,108
| +180% | +$3.85M | ﹤0.01% | 2152 |
|
|
2018
Q3 | $3.05M | Sell |
185,010
-36,340
| -16% | -$644K | ﹤0.01% | 2635 |
|
|
2018
Q2 | $3.1M | Sell |
221,350
-191,105
| -46% | -$2.74M | ﹤0.01% | 2531 |
|
|
2018
Q1 | $4.56M | Sell |
412,455
-93,120
| -18% | -$1.02M | ﹤0.01% | 2235 |
|
|
2017
Q4 | $4.45M | Buy |
505,575
+180,885
| +56% | +$1.94M | ﹤0.01% | 2217 |
|
|
2017
Q3 | $4.33M | Sell |
324,690
-49,035
| -13% | -$649K | ﹤0.01% | 2190 |
|
|
2017
Q2 | $5.36M | Buy |
373,725
+42,233
| +13% | +$812K | ﹤0.01% | 2015 |
|
|
2017
Q1 | $7.01M | Buy |
331,492
+75,121
| +29% | +$1.85M | ﹤0.01% | 1775 |
|
|
2016
Q4 | $7.22M | Buy |
+256,371
| New | +$7.17M | ﹤0.01% | 1756 |
|
|
2015
Q2 | – | Sell |
-40,225
| Closed | -$1.23M | – | 4028 |
|
|
2015
Q1 | $1.23M | Buy |
+40,225
| New | +$1.04M | ﹤0.01% | 2822 |
|
Other funds holding CHRS
RCMNY
TCM
KKRC
CM
Ameriprise's CHRS Position: Q4 2024 in Review
Ameriprise sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 61,449 shares — an estimated $63.9K sold.
Ameriprise first reported a position in CHRS in Q1 2015 and held it in 32 quarters. The position peaked at $68.4M in Q2 2020. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.
- Ameriprise reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
- Ameriprise sold 61,449 Coherus Oncology shares in Q4 2024, an estimated $63.9K.
- Ameriprise first reported a position in Coherus Oncology in Q1 2015 and held it in 32 quarters.
- Ameriprise's Coherus Oncology position peaked at $68.4M in Q2 2020.
- 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.
Based on Ameriprise's 13F filing for Q4 2024, filed 14 Feb 2025.